Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on April 5, 2019. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Rachelle Jacques to the Board of Directors, effective April 5, 2019. Ms. Jacques brings experience as the CEO of Enzyvant Therapeutics, Inc., and previously held senior roles at Alexion Pharmaceuticals, Shire plc, and Baxter International.
Compensation and Governance Details
- Compensation: Ms. Jacques will receive an initial option grant to purchase 68,000 shares of common stock, an annual cash retainer of $35,000 (pro-rated for the current year), and an annual stock option grant.
- Indemnification: The Company entered into a standard indemnification agreement with Ms. Jacques, covering expenses, judgments, and penalties incurred in her capacity as a director.
- Disclosure: A press release regarding this appointment was issued on April 8, 2019, and is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact terms of the initial 68,000-share option grant and vesting schedule.
- Confirm the pro-rated calculation for the $35,000 annual retainer for the 2019 fiscal year.
- Review the full text of the Indemnification Agreement (referenced as Exhibit 10.15 to the 2014 S-1 Amendment) for specific limitations.
- Check subsequent filings for Ms. Jacques' participation in the next annual stockholder meeting.